Related Experiment Videos
Freeze dried cryoprecipitate: a clinical evaluation.
Journal of Clinical Pathology
|May 1, 1983
Summary
Freeze-dried cryoprecipitate effectively treated hemophilia A patients, showing high factor VIII recovery. This accessible treatment may help meet the UK's factor VIII needs.
Area of Science:
- Hematology
- Biotechnology
Background:
- Hemophilia A requires factor VIII replacement therapy.
- Cryoprecipitate is a source of factor VIII.
- Freeze-drying offers a stable, accessible preparation method.
Purpose of the Study:
- To evaluate the efficacy and safety of freeze-dried cryoprecipitate in treating hemophilia A.
- To assess the in vivo recovery of factor VIII from this preparation.
Main Methods:
- Treatment of 14 hemophilia A patients with freeze-dried cryoprecipitate.
- Measurement of in vivo factor VIII recovery.
Main Results:
- Achieved 91.2% in vivo factor VIII recovery, comparable to European standards.
- Demonstrated product efficacy with no reported adverse effects.
Conclusions:
- Freeze-dried cryoprecipitate is an effective and safe treatment for hemophilia A.
- Its high yield and low-technology production may address factor VIII supply shortages in the UK.